ICON Public Limited Company Q2 FY2026 earnings call

• Demand & Bookings Performance

  • Q2 2026 gross business wins hit $3.7 billion, up 24% year-over-year and 13% sequentially. Cancellations were $562 million (in line with expectations), resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x. Direct fee net booked-to-bill ratio was 1.2x.
  • RFP flow increased 22% sequentially and 16% on a trailing 12-month basis. Large pharma RFP flow moderated from two prior very strong quarters, while biotech RFP flow saw a marked uptick aligned with ICON's strategic goal of expanding in the biotech market. Phase 3 opportunities represented ~50% of total opportunity volume, up from a ~40% average one year ago, indicating customers are moving more assets into later development stages.
  • Awards were broad-based: 8 of ICON's top 10 customers by awards in the quarter were midsize or biotech companies, and 13 individual wins each exceeded $50 million in value from 11 different customers across large pharma, midsize, and biotech sectors.
  • Oncology remains the largest therapeutic segment by revenue, while cardiometabolic opportunity flow and awards are now broadly comparable, driven by growing interest in obesity and adjacent indications among biotech customers.

• Strategic Priorities & Investments

  • Three core corporate priorities: expanding opportunity flow in biotech, diversifying sales channels within large pharma, and increasing market share with midsized pharmaceutical customers. Management reports tangible progress across all three areas.
  • Cross-selling to biotech customers has seen notable improvement: the share of biotech proposals that include ICON's central lab services has increased from the high 50% range a year ago to the mid 70% range currently, as the company aligns internal teams to deliver a holistic service offering.
  • AI is a foundational investment focus: ICON pursues a targeted strategy of embedding domain-specific AI into clinical workflows rather than generic enterprise AI licensing. The recently announced multi-year collaboration with Anthropic, paired with an existing partnership with Microsoft, will strengthen the technology architecture for ICON's Orbis agentic AI platform, improve productivity, and embed specialized AI agents into core trial management workflows. The Meridian multi-agent clinical monitoring platform is already being rolled out to ICON's global monitoring organization.
  • Asia-Pacific expansion: ICON has expanded its laboratory capabilities in China (adding specialty biomarker testing and pathology) following prior investment in Singapore, building out a regional lab footprint. The company won a new full-service partnership (including labs and imaging) with a leading Chinese biotech in the quarter. Full year 2026 China revenue is on track to grow ~20% year-over-year.

• Capital Allocation

  • ICON ended the quarter with a strong balance sheet: $928.4 million in cash, $3.4 billion in total debt, and a net debt position of $2.5 billion, down from $2.6 billion at the end of Q1 2026. The leverage ratio is 1.8x net debt to adjusted trailing 12-month EBITDA. The company remains committed to a balanced capital framework: investing in growth initiatives, pursuing strategic opportunities, and returning capital to shareholders.

ICON does not break out financial performance by separate product segments in this call. Overall consolidated Q2 2026 results are: total revenue of $2.1 billion, up 1.2% year-over-year and 1.4% sequentially (0.4% year-over-year on a constant currency basis). Adjusted EBITDA was $327.2 million, up 3% sequentially, with an adjusted EBITDA margin of 15.9% (30 basis points of sequential margin expansion). Adjusted gross margin was 23.8% (down from 29.1% in Q2 2025, impacted by elevated pass-through activity). Adjusted SG&A expense was $164.5 million (8% of revenue, down from 8.6% of revenue in Q2 2025, driven by one-time non-recurring R&D tax credit benefits). Adjusted net income was $198.4 million, equal to adjusted diluted EPS of $2.56. U.S. GAAP net income was $72.6 million, or $0.94 per diluted share. Operating cash flow was $281.3 million, capital expenditure was $42.4 million, resulting in free cash flow of $238.9 million. Customer concentration breakdown: top 5 customers represented 24% of total revenue, top 10 customers 40% of total revenue, and top 25 customers 65% of total revenue, unchanged from Q1 2026.

• Management reaffirmed its full year 2026 financial guidance, maintaining the previously published revenue and adjusted EPS ranges. The original guidance assumed pass-through activity would be broadly flat year-over-year.
  • Higher-than-expected pass-through activity in Q2 means full year pass-through levels are now more likely to exceed the prior flat year-over-year assumption. Higher pass-through will boost total revenue but lower reported full year EBITDA margin percentage; if pass-through remains elevated through the second half, revenue will land at the upper end of the guided range, and full year EBITDA margin will come in around the low 16% range (down from the prior midpoint expectation of ~16.5%).
  • Management remains focused on delivering sequential growth in adjusted EBITDA dollars rather than hitting a specific margin percentage target, and expects EBITDA dollar progression in the second half of 2026, with gross margin expansion driving this improvement after the one-time Q2 SG&A benefit. The underlying full year direct revenue assumption of a ~2% organic year-over-year decline remains unchanged, including the inorganic drag from the divestment of Symphony, which will create a larger year-over-year revenue headwind in H2 than it did in H1.
  • ICON expects the 2026 full year adjusted effective tax rate to remain approximately 17%.
  • Management plans to resume share repurchases in Q3 2026 and the back half of 2026, with no change to the company's capital return priorities.

• Elevated pass-through activity, driven by therapeutic mix, geographic trial location, and healthcare cost inflation, creates volatility in reported revenue and margin percentages, even as it does not impact ICON's core ability to deliver profitable EBITDA growth.
  • Quarterly RFP flow and demand can be volatile across customer segments, with normal quarter-over-quarter fluctuations in large pharma activity creating temporary swings in overall reported demand.
  • Forward-looking results are dependent on the rate at which current backlog is converted to revenue (burn rate), which is mathematically suppressed following three consecutive strong booking quarters, creating uncertainty around near-term revenue conversion timing.
  • Expansion into new portions of the biotech market leads to a higher proportion of exploratory/ballpark proposals and temporarily lower win rates as ICON engages with first-time customers, which could delay the impact of this strategic expansion on profitability.
  • Actual results may differ materially from forward-looking guidance due to unanticipated changes in economic conditions, industry dynamics, and clinical development trends, as outlined in the company's most recent Form 20-F filing.

Q: Demand is improving overall, with much of the strength driven by elevated pass-through activity. Is biotech demand actually slowing, and could higher pass-through push full year revenue above the guided range? / A: Management clarified biotech demand actually accelerated markedly in Q2, while large pharma RFP flow only moderated after two prior very strong quarters, which is normal quarterly volatility. Higher pass-through is driven by therapeutic mix and geographic trial location preferences. It is possible that sustained higher pass-through would push full year revenue to the upper end of the existing guided range, with a corresponding mechanical impact on reported margin, but the Symphony divestment will create a larger revenue headwind in H2 that offsets some of this gain. Management remains focused on growing EBITDA dollars regardless of pass-through mix. (317 characters)

Q: Given higher-than-expected pass-through, how should we model full year EBITDA margin, and how are cost reduction initiatives tracking? / A: The prior midpoint guidance implied a full year adjusted EBITDA margin of ~16.5%. If pass-through remains elevated and revenue lands at the top of the guided range while EPS hits the midpoint, the full year margin will mechanically shift down to the low 16% range. Cost actions are on track, and their benefits will be fully realized in the second half of the year as already built into the existing guidance range. (279 characters)

Q: Can you provide more context on what is driving the elevated pass-through levels, and what value will the new Anthropic AI partnership deliver? / A: Beyond therapeutic mix (large, expensive programs in cardiometabolic/oncology), pass-through is also elevated due to sustained US healthcare inflation and a industry trend of running more trials in the expensive US market. The Anthropic partnership builds on the existing Microsoft infrastructure partnership to embed frontier AI models directly into ICON's clinical workflows, rather than deploying generic AI tools. It will improve decision speed, reduce administrative work, and enhance productivity across functions like clinical monitoring, protocol drafting, and site selection, with value delivered incrementally through embedded tools rather than overnight transformation. (392 characters)

Q: Can you frame the long-term growth opportunity in China, particularly for your lab business? / A: There has been a notable, significant uptick in clinical development opportunity in China over the past year, driven by growth in both domestic Chinese innovation and global trial activity. ICON currently has over 1,500 employees in-country, and full year 2026 revenue is on track to grow ~20% year-over-year. The recent new partnership is a full-service global development agreement that includes lab and imaging capabilities, not just lab work. ICON is positioned to serve three key customer groups: Western companies running trials in China, Chinese companies running domestic trials, and Chinese biotechs seeking global partners for international development. (341 characters)